COMP <GO>
AXSM vs JNJ // 10Y YIELD & FRED MACRO BETA
Axsome Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: AXSM 2
— JNJ 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: AXSM
LAST: $144.43 (+0.68%) • MKT CAP: $7.51B
macro-sensitivity
1.15
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXSM VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXSM | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.90% | 25.50% | -47.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.25% | 2.97% | -4.22 | JNJ | /fcf-yield <GO> |
| Operating Margin | -26.10% | 34.70% | -60.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -28.70% | 28.50% | -57.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 65.50% | 6.00% | +59.50 | AXSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.34 | 5.59 | -0.25 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.20% | +0.20 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 24.3 | 60.4 | -36.03 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.15 | 1.08 | +0.07 | AXSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 23.0x | +12.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.51B | $662.49B | -$654.98B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXSM REV | JNJ REV | AXSM GROSS % | JNJ GROSS % | AXSM FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $638.5M | $94.19B | 44.0% | 67.9% | -$93.9M | $19.70B |
| FY 2024 | $385.7M | $88.82B | 44.0% | 69.1% | -$128.7M | $19.84B |
| FY 2023 | $270.6M | $85.16B | 44.0% | 44.0% | -$157.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXSM // BETA 1.15
JNJ // BETA 1.08